ARCTICZYMES TECHNOLOGIES ASA (AZT.OL) Stock Fundamental Analysis
OSL:AZT - Euronext Oslo - NO0010014632 - Common Stock - Currency: NOK
We assign a fundamental rating of 5 out of 10 to AZT. AZT was compared to 71 industry peers in the Biotechnology industry. Both the profitability and the financial health of AZT get a neutral evaluation. Nothing too spectacular is happening here. While showing a medium growth rate, AZT is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
AZT had positive earnings in the past year.
In the past year AZT had a positive cash flow from operations.
In the past 5 years AZT has always been profitable.
Each year in the past 5 years AZT had a positive operating cash flow.
1.2 Ratios
AZT's Return On Assets of 2.20% is amongst the best of the industry. AZT outperforms 80.28% of its industry peers.
With a decent Return On Equity value of 2.34%, AZT is doing good in the industry, outperforming 74.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.2% | ||
| ROE | 2.34% | ||
| ROIC | N/A |
ROA(3y)6.07%
ROA(5y)14.4%
ROE(3y)6.72%
ROE(5y)16.37%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AZT has a Profit Margin of 7.26%. This is amongst the best in the industry. AZT outperforms 80.28% of its industry peers.
In the last couple of years the Profit Margin of AZT has declined.
AZT has a better Gross Margin (94.27%) than 91.55% of its industry peers.
AZT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 7.26% | ||
| GM | 94.27% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-41.5%
PM growth 5YN/A
GM growth 3Y-0.94%
GM growth 5Y-0.64%
2. Health
2.1 Basic Checks
AZT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AZT has more shares outstanding
AZT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for AZT has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 25.06 indicates that AZT is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 25.06, AZT belongs to the top of the industry, outperforming 97.18% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that AZT is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.01, AZT belongs to the top of the industry, outperforming 81.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 25.06 |
ROIC/WACCN/A
WACC8.58%
2.3 Liquidity
AZT has a Current Ratio of 17.23. This indicates that AZT is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 17.23, AZT belongs to the best of the industry, outperforming 98.59% of the companies in the same industry.
AZT has a Quick Ratio of 16.28. This indicates that AZT is financially healthy and has no problem in meeting its short term obligations.
AZT has a Quick ratio of 16.28. This is amongst the best in the industry. AZT outperforms 98.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.23 | ||
| Quick Ratio | 16.28 |
3. Growth
3.1 Past
AZT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -62.16%.
Measured over the past years, AZT shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -45.53% on average per year.
AZT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -12.26%.
The Revenue has been growing by 18.22% on average over the past years. This is quite good.
EPS 1Y (TTM)-62.16%
EPS 3Y-45.53%
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-12.26%
Revenue growth 3Y-6.57%
Revenue growth 5Y18.22%
Sales Q2Q%-6.85%
3.2 Future
Based on estimates for the next years, AZT will show a very strong growth in Earnings Per Share. The EPS will grow by 63.87% on average per year.
Based on estimates for the next years, AZT will show a very strong growth in Revenue. The Revenue will grow by 30.65% on average per year.
EPS Next Y26.25%
EPS Next 2Y69.87%
EPS Next 3Y63.87%
EPS Next 5YN/A
Revenue Next Year8.45%
Revenue Next 2Y14.04%
Revenue Next 3Y15.71%
Revenue Next 5Y30.65%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 118.21, AZT can be considered very expensive at the moment.
Based on the Price/Earnings ratio, AZT is valued a bit cheaper than 78.87% of the companies in the same industry.
AZT's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.87.
Based on the Price/Forward Earnings ratio of 93.64, the valuation of AZT can be described as expensive.
AZT's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AZT is cheaper than 78.87% of the companies in the same industry.
AZT's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.38.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 118.21 | ||
| Fwd PE | 93.64 |
4.2 Price Multiples
AZT's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. AZT is cheaper than 73.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 127.03 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
AZT's earnings are expected to grow with 63.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.5
PEG (5Y)N/A
EPS Next 2Y69.87%
EPS Next 3Y63.87%
5. Dividend
5.1 Amount
AZT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:AZT (4/29/2025, 11:03:54 AM)
16.55
+0.3 (+1.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners15.46%
Inst Owner ChangeN/A
Ins Owners15.57%
Ins Owner ChangeN/A
Market Cap845.21M
Analysts76.67
Price Target19.38 (17.1%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)574.26%
Min EPS beat(2)-139.6%
Max EPS beat(2)1288.12%
EPS beat(4)1
Avg EPS beat(4)272.1%
Min EPS beat(4)-139.6%
Max EPS beat(4)1288.12%
EPS beat(8)3
Avg EPS beat(8)143.63%
EPS beat(12)4
Avg EPS beat(12)86.39%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-8.18%
Min Revenue beat(2)-18.99%
Max Revenue beat(2)2.64%
Revenue beat(4)1
Avg Revenue beat(4)-7.11%
Min Revenue beat(4)-18.99%
Max Revenue beat(4)2.64%
Revenue beat(8)2
Avg Revenue beat(8)-7.58%
Revenue beat(12)3
Avg Revenue beat(12)-4.81%
Revenue beat(16)6
Avg Revenue beat(16)-3.81%
PT rev (1m)0%
PT rev (3m)11.76%
EPS NQ rev (1m)-12.5%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-14.63%
EPS NY rev (3m)-70.34%
Revenue NQ rev (1m)-1.85%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.28%
Revenue NY rev (3m)-5.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 118.21 | ||
| Fwd PE | 93.64 | ||
| P/S | 8.1 | ||
| P/FCF | N/A | ||
| P/OCF | 480.51 | ||
| P/B | 2.61 | ||
| P/tB | 2.91 | ||
| EV/EBITDA | 127.03 |
EPS(TTM)0.14
EY0.85%
EPS(NY)0.18
Fwd EY1.07%
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)0.03
OCFY0.21%
SpS2.04
BVpS6.33
TBVpS5.68
PEG (NY)4.5
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.2% | ||
| ROE | 2.34% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 7.26% | ||
| GM | 94.27% | ||
| FCFM | N/A |
ROA(3y)6.07%
ROA(5y)14.4%
ROE(3y)6.72%
ROE(5y)16.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-41.5%
PM growth 5YN/A
GM growth 3Y-0.94%
GM growth 5Y-0.64%
F-Score4
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.83 | ||
| Cap/Depr | 144.69% | ||
| Cap/Sales | 9.12% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 33.5% | ||
| Profit Quality | N/A | ||
| Current Ratio | 17.23 | ||
| Quick Ratio | 16.28 | ||
| Altman-Z | 25.06 |
F-Score4
WACC8.58%
ROIC/WACCN/A
Cap/Depr(3y)231.16%
Cap/Depr(5y)215.23%
Cap/Sales(3y)11.45%
Cap/Sales(5y)9.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.16%
EPS 3Y-45.53%
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y26.25%
EPS Next 2Y69.87%
EPS Next 3Y63.87%
EPS Next 5YN/A
Revenue 1Y (TTM)-12.26%
Revenue growth 3Y-6.57%
Revenue growth 5Y18.22%
Sales Q2Q%-6.85%
Revenue Next Year8.45%
Revenue Next 2Y14.04%
Revenue Next 3Y15.71%
Revenue Next 5Y30.65%
EBIT growth 1Y-108.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year400%
EBIT Next 3Y135.99%
EBIT Next 5YN/A
FCF growth 1Y-248.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-92.8%
OCF growth 3Y-71.37%
OCF growth 5Y-15.01%